Value based designs work: CVS study results

Value-Based Insurance Design and Antidiabetic Medication Adherence

VOL. 2, NO. 1 • The American Journal of Pharmacy Benefits

Authors:  Andrew Chang, MPH; Joshua N. Liberman, PhD; Charmaine Coulen, MPH; Jan E. Berger, MD, MJ; and Troyen A. Brennan, MD, JD


Objective: To evaluate the impact on adherence to antidiabetic pharmacotherapy of implementing a value-based insurance design (VBID).

Value-based insurance designs selectively lower or even eliminate copayments for highly effective preventive medications prescribed for the management of chronic health conditions in an effort to improve medication adherence, improve health outcomes, and lower healthcare costs.11,12 Hence, insurers are  increasingly drawn to VBID for medications indicated for prevalent health conditions for which empirical evidence suggests that treatment adherence will improve outcomes.

Download the entire study here